Table 2 Characteristics of included studies
Study year | Country | Study interval | Original tumor state | Radical cystectomy timing | Bladder preservation modality | Male/female (BP vs RC) | Study size (BP vs RC) | Age (BP vs RC) | Median follow-up time (BP vs RC) | Types of outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
Hautmann 2009 | Germany | 1986–1908 | T1G3 | Within 3 mo | BCG | Ratio 4:1 | 99 vs 175 | 63.9 | 58 mo | CSS PFS |
Jager 2011 | Germany | 1989–2006 | HGNMIBC | Median 4 mo | Endoscopic treatment/IVT | 236 vs 42 | 43 vs 235 | 66 | 79 mo | CSS |
Thalmann2004 | Switzerland | 1980–1999 | T1G3 | Within 3 mo | BCG | 71/21 vs 26/3 | 92 vs 29 | 69 vs 66 | 82.8 mo | OS CSS PFS |
De Berardinis 2011 | Italy | 1995–2001 | T1G3 | Within 2 mo | BCG | 60/20 vs 49/23 | 80 vs 72 | 70.4 vs 69.6 | 99.6 mo | OS CSS PFS |
Denzinger 2008 | Germany | 1990–2005 | T1G3 | UN | BCG | 95/30 vs 71/27 | 125 vs 98 | 73 vs 71 | 56 mo vs 51 mo | OS CSS |
Li 2011 | China | 1995–2007 | T1G3 | 3 mo | BCG | 18/14 vs 10/6 | 32 vs 16 | 61 vs 58 | 66 mo vs 72 mo | OS CSS |
Patard 2001 | France | 1979–1996 | T1G3 | Median 16 mo | BCG | UN | 50 vs 14 | 62.52 vs 62.78 | 62 mo | CSS |
Sun 2008 | China | 199–2007 | T1G3 | UN | BCG/MMC/EPI /HCOT | 68/13 vs 23/9 | 81 vs 32 | 66 vs 64 | 64 mo vs 62 mo | OS CSS |
Badalato 2012 | USA | 1990–2010 | HGT1 | Within 3 mo | Observation /IVT | 88/25 vs 168/68 | 236 vs 113 | 69.5 vs 68.3 | 46.4 mo vs 51.5 mo | CSS |
Spaliviero 2014 | USA | 2000–2012 | HGT1 | Within 3 mo | Observation /BCG | Ratio 3:1 | 21 vs 15 | 68 | 38.4 mo | CSS |
Wong 2009 | UK | 1998–2007 | HGNMIBC | UN | BCG | UN | 41 vs 36 | 67.23 | 53 mo | OS |